NGNE (Neurogene) Net Income From Continuing Operations : $-80.87 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Neurogene's net income from continuing operations for the three months ended in Mar. 2025 was $-22.65 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was $-80.87 Mil.

Neurogene Net Income From Continuing Operations Historical Data

The historical data trend for Neurogene's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Net Income From Continuing Operations Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

-50.52

-55.19

-36.32

-75.14

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial							-16.92	-18.49	-20.22	-19.51	-22.65

Neurogene Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-80.87 Mil.

Neurogene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

UU8:Germany

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.